# Adaptive Trial Design Agent

**ID:** `biomedical.clinical.adaptive_trial`
**Version:** 1.0.0
**Status:** Beta
**Category:** Clinical AI / Trial Design

---

## Overview

The **Adaptive Trial Design Agent** uses Bayesian frameworks and reinforcement learning to design and optimize clinical trials that can modify key parameters based on accumulating data. Adaptive designs can reduce sample sizes, identify optimal doses faster, and improve success rates.

---

## Key Capabilities

### 1. Adaptive Elements

| Element | Adaptation | Benefit |
|---------|------------|---------|
| **Sample size** | Re-estimation | Efficiency |
| **Randomization** | Response-adaptive | Ethics |
| **Dose** | Dose-finding | Speed |
| **Endpoint** | Biomarker-guided | Precision |
| **Population** | Enrichment | Success rate |

### 2. Design Types

| Design | Description | Use Case |
|--------|-------------|----------|
| **Bayesian adaptive** | Prior updating | Early phase |
| **MAMS** | Multi-arm multi-stage | Platform trials |
| **Basket/Umbrella** | Biomarker-driven | Precision medicine |
| **Seamless II/III** | Phase combination | Acceleration |

### 3. Analysis Methods

- **Bayesian inference:** Posterior probability of success
- **Futility analysis:** Early stopping for harm/futility
- **Interim analysis:** Prespecified data looks
- **RL optimization:** Optimal allocation policies

---

## Usage

### Example Prompt

```text
Design an adaptive Phase II trial for a novel immunotherapy.

Requirements:
- 3 dose levels + control
- Response-adaptive randomization
- Bayesian interim analysis at 50%, 75% enrollment
- Futility stopping rules
- Sample size re-estimation
```

### Expected Output

```
## Adaptive Trial Design: Immunotherapy Phase II

### Design Overview
| Element | Specification |
|---------|---------------|
| **Phase** | II |
| **Arms** | 4 (control + 3 doses) |
| **Initial N** | 40 per arm (160 total) |
| **Max N** | 240 |
| **Primary endpoint** | ORR |

### Adaptation Rules

#### Response-Adaptive Randomization
| Interim | Method | Rationale |
|---------|--------|-----------|
| Start | 1:1:1:1 equal | Initial learning |
| 50% | BAR | Shift toward effective doses |
| 75% | BAR (more aggressive) | Maximize information |

#### Futility Stopping (Bayesian)
| Criterion | Threshold | Action |
|-----------|-----------|--------|
| P(ORR > control) < 0.05 | All doses | Stop for futility |
| P(ORR < 10%) > 0.90 | Per dose | Drop dose arm |

#### Efficacy (Interim)
| Criterion | Threshold | Action |
|-----------|-----------|--------|
| P(ORR > 30%) > 0.95 | Best dose | Consider early success |

### Sample Size Re-estimation
At 75% interim:
- If conditional power 30-80% → Increase N up to 240
- If conditional power >80% → No change
- If conditional power <30% → Consider stopping

### Operating Characteristics (Simulation)
| Scenario | Power | Expected N | % Early Stop |
|----------|-------|------------|--------------|
| H0 (all ORR=15%) | 5% | 145 | 65% (futility) |
| HA (best=40%) | 88% | 178 | 12% (efficacy) |
| Dose-response | 85% | 185 | 8% |
```

---

## References

- **Berry et al. (2010):** "Bayesian Adaptive Methods for Clinical Trials"
- **FDA Guidance (2019):** "Adaptive Designs for Clinical Trials of Drugs and Biologics"

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
